We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors.
- Authors
Moore, M; Hirte, H W; Siu, L; Oza, A; Hotte, S J; Petrenciuc, O; Cihon, F; Lathia, C; Schwartz, B
- Abstract
BAY 43--9006, an oral multi-kinase inhibitor, targets serine-threonine kinases and receptor tyrosine kinases, and affects the tumor and vasculature in preclinical models. Based on its pharmacologic effect, it may be a useful cancer treatment. This study determined the maximum tolerated dose (MTD) of BAY 43-9006 in 42 patients with advanced, refractory metastatic or recurrent solid tumors. Dose-limiting toxicities (DLTs), safety, pharmacokinetics and tumor response were also evaluated.
- Publication
Annals of oncology : official journal of the European Society for Medical Oncology, 2005, Vol 16, Issue 10, p1688
- ISSN
0923-7534
- Publication type
Journal Article
- DOI
10.1093/annonc/mdi310